Literature DB >> 9161113

A comparison of time trade-off and quality of life measures in patients with advanced cancer.

D J Perez1, R McGee, A V Campbell, E A Christensen, S Williams.   

Abstract

Quality of life (QOL) measures are now accepted as indicators of efficacy in the palliative treatment of cancer. Utility measures may also provide valuable information in this area yet they have rarely been applied. To assess the concordance of QOL and utility scales, 93 patients with advanced, symptomatic cancer completed two QOL instruments, the Spitzer Quality of Life Index (QLI) and Spitzer Uniscale, and a time-trade off (TTO) question reflecting the utility of their health states. The scales were self-administered. All patients completed the QLI and Uniscale but only 37% of participants were prepared to trade time. The remainder comprised 39% who felt too well to trade time and 24% who did not wish to consider trading time at all. Those prepared to trade time had significantly worse scores on both QLI and Uniscale instruments than those who felt too well to trade. However the correlation between time traded and QLI and Uniscale scores was poor. We conclude that the TTO question used in this study, while not strongly related to QOL, provides a measure of the patient's attitude to their health state. This may explain why patients differ in their attitude to quantity vs. quality of life.

Entities:  

Mesh:

Year:  1997        PMID: 9161113     DOI: 10.1023/a:1026438100283

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  13 in total

Review 1.  Quality of life end points in cancer clinical trials: review and recommendations.

Authors:  C M Moinpour; P Feigl; B Metch; K A Hayden; F L Meyskens; J Crowley
Journal:  J Natl Cancer Inst       Date:  1989-04-05       Impact factor: 13.506

2.  Quality of life in patients with inflammatory bowel disease.

Authors:  A Mitchell; G Guyatt; J Singer; E J Irvine; R Goodacre; C Tompkins; N Williams; F Wagner
Journal:  J Clin Gastroenterol       Date:  1988-06       Impact factor: 3.062

3.  The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group.

Authors:  A Laupacis; C Wong; D Churchill
Journal:  Control Clin Trials       Date:  1991-08

Review 4.  Utility approach to measuring health-related quality of life.

Authors:  G W Torrance
Journal:  J Chronic Dis       Date:  1987

5.  Measuring quality of life: risks and benefits.

Authors:  H Schipper; M Levitt
Journal:  Cancer Treat Rep       Date:  1985-10

Review 6.  Measurement of quality of life in clinical trials of therapy.

Authors:  A E Fletcher; C J Bulpitt
Journal:  Cardiology       Date:  1988       Impact factor: 1.869

Review 7.  Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life.

Authors:  D A Revicki; R M Kaplan
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

8.  Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

Authors:  W O Spitzer; A J Dobson; J Hall; E Chesterman; J Levi; R Shepherd; R N Battista; B R Catchlove
Journal:  J Chronic Dis       Date:  1981

9.  Measurement of quality of life in end-stage renal disease: the time trade-off approach.

Authors:  D N Churchill; G W Torrance; D W Taylor; C C Barnes; D Ludwin; A Shimizu; E K Smith
Journal:  Clin Invest Med       Date:  1987-01       Impact factor: 0.825

10.  Choices in oncology: factors that influence patients' treatment preference.

Authors:  G M Kiebert; A M Stiggelbout; J Kievit; J W Leer; C J van de Velde; H J de Haes
Journal:  Qual Life Res       Date:  1994-06       Impact factor: 4.147

View more
  9 in total

1.  Adjusting distributions of the Health Utilities Index Mark 3 utility scores of health-related quality of life.

Authors:  Jian Sun
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

2.  A longitudinal study of health related quality of life and utility measures in patients with advanced breast cancer.

Authors:  D J Perez; S M Williams; E A Christensen; R O McGee; A V Campbell
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

3.  Quality of life after curative liver resection: a single center analysis.

Authors:  Helge Bruns; Kirsten Krätschmer; Ulf Hinz; Anette Brechtel; Monika Keller; Markus-W Büchler; Peter Schemmer
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

4.  Health values of patients with bipolar disorder.

Authors:  J Tsevat; P E Keck; R W Hornung; S L McElroy
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

5.  Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Canadian Collaborative Cardiac Assessment Group.

Authors:  L Lalonde; A E Clarke; L Joseph; T Mackenzie; S A Grover
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

6.  Long-term quality of life after hepatic resection: health is not simply the absence of disease.

Authors:  Vanessa M Banz; Daniel Inderbitzin; Regula Fankhauser; Peter Studer; Daniel Candinas
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

7.  Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method.

Authors:  Hans-Helmut König; Oliver H Günther; Matthias C Angermeyer; Christiane Roick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Quality of life versus length of life considerations in cancer patients: A systematic literature review.

Authors:  Anne Shrestha; Charlene Martin; Maria Burton; Stephen Walters; Karen Collins; Lynda Wyld
Journal:  Psychooncology       Date:  2019-05-15       Impact factor: 3.894

9.  Self-esteem in patients with venous thromboembolism predicts time trade-off values for own health.

Authors:  Peep F M Stalmeier; Eva E Volmeijer
Journal:  Health Qual Life Outcomes       Date:  2022-03-05       Impact factor: 3.186

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.